[ad_1] HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso’s PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/-…
[ad_1] HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso’s PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/-…